Detalhe da pesquisa
1.
Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.
Hepatology
; 77(1): 77-91, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35567547
2.
Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.
Hepatol Res
; 53(4): 301-311, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36507871
3.
Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.
Hepatol Res
; 52(3): 298-307, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34918428
4.
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
Hepatol Res
; 52(7): 630-640, 2022 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35417606
5.
Clinical course of hepatitis C virus-positive patients with decompensated liver cirrhosis in the era of direct-acting antiviral treatment.
Hepatol Res
; 51(5): 517-527, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33507588
6.
Lower Serum Sodium Levels Are Associated with the Therapeutic Effect of Sorafenib on Hepatocellular Carcinoma.
Dig Dis Sci
; 66(5): 1720-1729, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32556820
7.
Hypovascular hepatic nodules as a predictive factor for transcatheter arterial chemoembolization refractoriness in hepatocellular carcinoma.
Hepatol Res
; 50(3): 365-373, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31661722
8.
Initial treatment response to transarterial chemoembolization as a predictive factor for Child-Pugh class deterioration prior to refractoriness in hepatocellular carcinoma.
Hepatol Res
; 50(11): 1275-1283, 2020 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-32812315
9.
Therapeutic efficacy of lenvatinib in hepatocellular carcinoma patients with portal hypertension.
Hepatol Res
; 50(9): 1091-1100, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32559342
10.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
PLoS One
; 18(2): e0281459, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36749777
11.
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
Cancers (Basel)
; 14(4)2022 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35205631
12.
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
Cancers (Basel)
; 14(14)2022 Jul 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35884434
13.
Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
Anticancer Res
; 41(4): 2187-2192, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33813432
14.
ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Clin Cancer Res
; 27(4): 1150-1161, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33288659
15.
Successful treatment of drug-induced esophageal ulcer in a patient with chronic heart failure: A case report.
Medicine (Baltimore)
; 97(48): e13380, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30508933